Parameters of Exercise to Prevent Osteoporosis

Completed · Not applicable

Conditions studied: Osteoporosis, Postmenopausal

In brief

The principal goal of this study is to determine parameters of walking in terms of peak mechanical vertical force, bout duration, and bout spacing that can preserve or increase bone mineral density (BMD) in postmenopausal women. Release of pulses of parathyroid hormone (PTH), growth hormone (GH), and of markers of bone resorption and bone formation will be used as indicators of the osteogenic effects of a short exposure to exercise. When secreted in pulsatile fashion, GH stimulates osteoblast proliferation, particularly in cortical bone (27, 28). Like GH, the pattern of PTH secretion determines the nature of its effect on bone. When it is secreted in pulsatile manner, PTH contributes to bone formation through activation of bone lining cells, differentiation of osteoprogenitor cells, and suppression of bone cell apoptosis .

Key facts

Study ID

NCT04063813

Run by

University of Michigan

People needed

40

Starts

2007-05-15

Expected to finish

2010-08-19

Last updated by the study team

2019-08-21

Who can join

Age: 50 and older, up to 65. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Age 50 to 65 years if naturally post-menopausal, or age 47 if surgically postmenopausal
• Dual energy X-ray absorptiometry (DEXA) Z score above -1
• No endocrine or metabolic disease requiring medication except for hormonally corrected hypothyroidism
• No musculo-skeletal disabilities that would preclude treadmill walking
• Normal electrocardiogram (EKG) and heart health history
• BMI between 24 and 30
• Hematocrit above 32 %
• No hormone replacement therapy (HRT)
• Personal health provider's Release Letter

You may not qualify if…

• Age and BMI outside of the specified range
• Z score below -1
• Medication for presence of metabolic or endocrine disease
• Musculo-skeletal disabilities that would preclude treadmill walking
• Abnormal electrocardiogram (EKG) and heart health history
• Hematocrit below 32%
• Hormone replacement therapy
• Failure to conform to study protocol

Where it is running

• Michigan Clinical Research Unit United States — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.